Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference

Company Overview - Genelux Corporation is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for patients with aggressive and difficult-to-treat solid tumors [4] - The company's most advanced product candidate, Olvi-Vec, is a modified strain of the vaccinia virus currently being evaluated in a Phase 3 trial for platinum-resistant/refractory ovarian cancer [4] Upcoming Events - Thomas Zindrick, President, CEO, and Chairman of the Board, will discuss clinical-stage programs and upcoming milestones at the Guggenheim Inaugural Healthcare Innovation Conference from November 11-13, 2024 [1] - The conversation with Brittany Stopa, MD, is scheduled for November 11, 2024, at 1:30 p.m. ET, with a webcast link available for the event [2] - The company will also participate in one-on-one meetings during the conference for institutional investors [3]